Amgen (AMGN) Tops Q3 EPS by 35c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Alaska LNG shipping savings justifies billions in investment, developer says
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180
October 29, 2015 10:46 AM EDTUBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.
Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More



